Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play
Bristol Myers Squibb will acquire Orbital Therapeutics for $1.5 billion in cash, pending regulatory approval. Orbital’s lead drug, OTX-201, is an in vivo CAR‑T therapy for autoimmune diseases and is expected to enter human trials in early 2026. BMS shares rose 0.3% to $44.68 on Oct 10, 2025. The deal is expected to close late 2025 or early 2026.